Status In progress
Process CDF Review
ID number 1536

Provisional Schedule

Appraisal consultation 15 November 2019 - 05 December 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Fight Bladder Cancer
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
15 November 2019 This appraisal (ID1536) is a review of pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519) following data collection via a managed access agreement. Patient access according to the terms of TA519 is unaffected by the draft recommendations of ID1536 while the review is ongoing.
22 October 2019 Committee meeting
26 June 2019 Invitation to participate
10 May 2019 In progress, Referred 22 July 2016

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance